Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Depreciation and Depletion (2016 - 2020)

Historic Depreciation and Depletion for Agios Pharmaceuticals (AGIO) over the last 9 years, with Q2 2020 value amounting to $2.4 million.

  • Agios Pharmaceuticals' Depreciation and Depletion rose 1939.13% to $2.4 million in Q2 2020 from the same period last year, while for Jun 2020 it was $8.9 million, marking a year-over-year increase of 1396.25%. This contributed to the annual value of $5.7 million for FY2024, which is 1363.64% down from last year.
  • According to the latest figures from Q2 2020, Agios Pharmaceuticals' Depreciation and Depletion is $2.4 million, which was up 1939.13% from $2.5 million recorded in Q1 2020.
  • Agios Pharmaceuticals' 5-year Depreciation and Depletion high stood at $2.5 million for Q1 2020, and its period low was $1.2 million during Q1 2016.
  • Its 5-year average for Depreciation and Depletion is $1.8 million, with a median of $1.7 million in 2018.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Depreciation and Depletion soared by 23675.68% in 2016, and later crashed by 580.72% in 2017.
  • Agios Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $1.7 million in 2016, then fell by 5.81% to $1.6 million in 2017, then increased by 19.54% to $1.9 million in 2018, then dropped by 3.25% to $1.9 million in 2019, then increased by 29.64% to $2.4 million in 2020.
  • Its Depreciation and Depletion stands at $2.4 million for Q2 2020, versus $2.5 million for Q1 2020 and $1.9 million for Q4 2019.